{
    "title": "105_hr1315",
    "content": "The Act titled \"Diabetes Research Amendments of 1997\" is cited as the short title. The Congress finds that diabetes affects 16 million Americans, with 650,000 new diagnoses in 1997. Diabetes is a leading cause of death, reducing life expectancy by 30%. The total healthcare costs exceed $130 billion annually. Diabetes is the top cause of new blindness cases and one-third of kidney dialysis patients have diabetes-related kidney failure. Diabetes is a significant risk factor for coronary artery disease, especially in women aged 30-55. Both Type I and Type II diabetes increase the risk of developing coronary artery disease. Diabetic neuropathy affects 90% of long-term diabetes patients and contributes to lower extremity amputations. Hypertension affects 60-65% of people with diabetes. African Americans, Hispanic Americans, and Native Americans are at higher risk of developing diabetes. Establishment of a plan for diabetes-related activities of the National Institutes of Health under section 3 of the Public Health Service Act. Sec. 432A requires the Director of the National Institute of Diabetes and Digestive and Kidney Diseases to establish a comprehensive plan for diabetes-related activities at the National Institutes of Health, prioritize these activities, and review the plan annually. The Director of the National Institute of Diabetes and Digestive and Kidney Diseases, along with the Diabetes Mellitus Interagency Coordinating Committee, must establish an initial plan for diabetes research within 12 months of the Diabetes Research Amendments of 1997. Additionally, a Diabetes Research-Plan Working Group will be established to provide advice on the development of this plan. The Working Group, as outlined in section 432A(b) of the Public Health Service Act, will consist of up to 30 members appointed by the Director of the National Institutes of Health. Representatives from specific agencies such as the National Institute of Diabetes and Digestive and Kidney Diseases, the National Eye Institute, and the National Heart, Lung, and Blood Institute will be included in the Working Group. The Working Group, appointed by the Director of the National Institutes of Health, includes representatives from various agencies such as the National Institute of Diabetes and Digestive and Kidney Diseases, the National Eye Institute, and other institutes like the National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Dental Research, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, and National Center for Human Genome Research. Private sector participation is also encouraged. The Working Group appointed by the Director of the National Institutes of Health includes individuals from the private sector such as leading diabetes researchers, healthcare industry leaders, and representatives of diabetes organizations. The chair of the group is selected by the Director and must be from the private sector. Appointments to the group must be completed by a specified date. The National Institutes of Health must appoint individuals to the Working Group within 90 days of the Act's enactment. The Working Group will terminate 30 days after submitting the diabetes plan to Congress. Section 433(1) of the Public Health Service Act is amended to include the diabetes plan under section 432A."
}